View More Recent Stories
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) reports TALVEY demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
-
BofA Securities Reiterates Neutral Rating on Johnson & Johnson (JNJ)
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) stock: 1Q24 earnings preview

